Stemline Israel Ltd.

CD123-directed cytotoxin. Tagraxofusp 1.15 mg/vial.
CD123-directed cytotoxin tagraxofusp
 VIAL: conc. for sol. for infus. 1X  1 mg/ml
Admin. at 12 mcg/kg IV over 15 min. 1/d on days 1 to 5 of a 21-d
cycle. Dosing period may be extend. for dose delays up to day 10 of the cycle. Cont. until dis. progress. or unaccept. tox.
Tmt. of blastic plasmacytoid dendritic cell neoplasm
(BPDCN) in adults
C/I:Hypersens.

Estrogen Receptor Antagonist. Elacestrant 86 mg, 345 mg.
FC tab 86/345 mg
345 mg once dly until dis. progress. or unaccept. tox.
tmt. of postmenopausal women or adlt. men with estrogen recept. (ER)-pos., human epidermal growth fact. recept. 2 (HER)-neg., ESR1-mutated adv. or metast. breast cancer with dis. progr. follow. at least 1 line of endocr. ther.
C/I: Hypersens.